A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

por Stoehlmacher, J, Park, D J, Zhang, W, Yang, D, Groshen, S, Zahedy, S, Lenz, H-J
Publicado 2004

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

por Iqbal, S., Goldman, B., Fenoglio-Preiser, C. M., Lenz, H. J., Zhang, W., Danenberg, K. D., Shibata, S. I., Blanke, C. D.
Publicado 2011

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)

por Louie, S G, Ely, B, Lenz, H-J, Albain, K S, Gotay, C, Coleman, D, Raghavan, D, Shields, A F, Gold, P J, Blanke, C D
Publicado 2013

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

por El-Khoueiry, A B, Rankin, C, Siegel, A B, Iqbal, S, Gong, I-Y, Micetich, K C, Kayaleh, O R, Lenz, H-J, Blanke, C D
Publicado 2014

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy

por Szkandera, J, Herzog, S, Pichler, M, Stiegelbauer, V, Stotz, M, Schaberl-Moser, R, Samonigg, H, Asslaber, M, Lax, S, Leitner, G, Renner, W, Lenz, H-J, Berghold, A, Gerger, A
Publicado 2015

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

por Sebio, A., Stintzing, S., Heinemann, V., Sunakawa, Y., Zhang, W., Ichikawa, W., Tsuji, A., Takahashi, T., Parek, A., Yang, D., Cao, S., Ning, Y., Stremitzer, S., Matsusaka, S., Okazaki, S., Barzi, A., Berger, M., Lenz, H-J
Publicado 2016

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

por Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V
Publicado 2015

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

por Van Cutsem, E, Yoshino, T, Lenz, H J, Lonardi, S, Falcone, A, Limón, M L, Saunders, M, Sobrero, A, Park, Y S, Ferreiro, R, Hong, Y S, Tomasek, J, Taniguchi, H, Ciardiello, F, Stoehr, J, Oum’Hamed, Z, Vlassak, S, Studeny, M, Argiles, G
Publicado 2018

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)

por Sunakawa, Y., Satake, H., Usher, J., Jaimes, Y., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., Watanabe, T., Ishiguro, K., Tanaka, C., Takeuchi, M., Fujii, M., Danenberg, K., Danenberg, P.V., Lenz, H.-J., Sekikawa, T., Ichikawa, W.
Publicado 2022

Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis

por Lee, Y S, Choi, I, Ning, Y, Kim, N Y, Khatchadourian, V, Yang, D, Chung, H K, Choi, D, LaBonte, M J, Ladner, R D, Nagulapalli Venkata, K C, Rosenberg, D O, Petasis, N A, Lenz, H-J, Hong, Y-K
Publicado 2012

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

por Koczywas, M, Frankel, P H, Synold, T W, Lenz, H-J, Mortimer, J E, El-Khoueiry, A B, Gandara, D R, Cristea, M C, Chung, V M, Lim, D, Reckamp, K L, Lau, D H, Doyle, L A, Ruel, C, Carroll, M I, Newman, E M
Publicado 2014

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

por Stintzing, S, Wirapati, P, Lenz, H -J, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, D P, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, Heinemann, V
Publicado 2019

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

por Yoshino, T., Cleary, J. M., Van Cutsem, E., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H. S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J.
Publicado 2020